Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MLTX MoonLake Immunotherapeutics
- Stocks
- Healthcare
- NASDAQ: MLTX
Price (delayed)
$37.62
Market cap
$2.42B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$2.22B
moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Highlights
MLTX's quick ratio has dropped by 67% year-on-year
MLTX's equity is down by 25% YoY and by 9% QoQ
Key stats
What are the main financial stats of MLTX
Market
Valuations
Earnings
Shares outstanding
64.2M
Market cap
$2.42B
Enterprise value
$2.22B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$170.76M
Net income
-$147.83M
EBIT
-$147.44M
EBITDA
-$145.71M
Free cash flow
-$140.12M
Per share
Balance sheet
Liquidity
EPS
-$2.3
EPS diluted
-$2.3
Free cash flow per share
-$2.22
Book value per share
$6.37
Revenue per share
$0
TBVPS
$8.09
Total assets
$511.26M
Total liabilities
$98.68M
Debt
$75.6M
Equity
$407.52M
Working capital
$482.28M
Debt to equity
0.19
Current ratio
21.11
Quick ratio
20.15
Net debt/EBITDA
1.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28.8%
Return on equity
-31.7%
Return on invested capital
-66.4%
Return on capital employed
-30.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLTX stock price
How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
-0.11%
1 week
-2.21%
1 month
1.76%
1 year
-7.93%
YTD
-30.53%
QTD
-3.71%
Financial performance
How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$170.76M
Net income
-$147.83M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 180% year-on-year and by 19% since the previous quarter
The net income has declined by 22% since the previous quarter
Price vs fundamentals
How does MLTX's price correlate with its fundamentals
Growth
What is MoonLake Immunotherapeutics's growth rate over time
Valuation
What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
5.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has decreased by 22% QoQ
MLTX's equity is down by 25% YoY and by 9% QoQ
The price to book (P/B) is 9% lower than the last 4 quarters average of 6.5
Efficiency
How efficient is MoonLake Immunotherapeutics business performance
The company's return on equity fell by 30% QoQ
The company's return on assets fell by 25% QoQ
The ROIC has contracted by 23% YoY but it has grown by 4.3% from the previous quarter
Dividends
What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLTX.
Financial health
How did MoonLake Immunotherapeutics financials performed over time
MLTX's quick ratio has dropped by 67% year-on-year
The current ratio has dropped by 66% year-on-year
The debt is 81% smaller than the equity
MLTX's equity is down by 25% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.